Articles tagged with Prostate Cancer
Research at Duke University Medical Center found that prostate cancer patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. The study analyzed outcomes of 8,736 men with metastatic prostate cancer and provides valuable information on prognosis and treatment approaches.
Researchers at Karolinska Institutet and University of Oulu identified mechanisms explaining genetic variants' influence on prostate cancer risk. The study reveals widespread deregulation of androgen receptor function, a key player in prostate cancer.
Researchers have found a possible association between radiotherapy for prostate cancer and an increased risk of developing secondary cancers of the bladder, colorectal tract, and rectum. However, the absolute rates of these secondary cancers remain low compared to other treatment complications.
A new study by Northwestern University research found that low levels of vitamin D are associated with aggressive prostate cancer in men. Men with dark skin or limited sun exposure should get their vitamin D levels checked and supplement if necessary to reduce the risk of aggressive prostate cancer.
A study by the University of Texas M.D. Anderson Cancer Center reveals that adult stem cells in the prostate basal cell layer express genes similar to those found in deadly prostate cancer, offering a potential new line of treatment for highly aggressive and therapy-resistant forms.
A new study from The Ottawa Hospital and the University of Ottawa shows that men with slow-growing prostate tumors are increasingly adopting active surveillance, a monitoring approach that avoids unnecessary treatment. After five years of follow-up, about 59% of patients under active surveillance were still managed that way.
A new clinical trial has begun at Oxford and Sheffield to test a potential vaccine for prostate cancer. The vaccine aims to stimulate the immune system's attack on cancer cells by recognizing a specific protein found on their surface. If successful, future studies will assess its effectiveness in preventing disease progression.
Researchers at UT Southwestern Medical Center found that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy. This technology aims to improve surgical decision-making and reduce the amount of healthy tissue removed during prostate cancer surgery.
Florida State University researchers are working on a new approach to deciphering genetic data that may lead to more targeted prostate cancer treatments. They identified altered signal pathways in prostate cancer, which could help pinpoint genetic changes that matter in cancer development and progression.
A new device can detect prostate cancer in urine samples using a gas chromatography sensor system, allowing for earlier diagnosis and potentially reducing the need for invasive procedures. The technology has shown promising results in a pilot study involving 155 men.
A study published in Circulation found that prostate cancer survivors are at higher risk of developing cardiovascular disease due to hormone therapy. The Vanderbilt Cardio-oncology program is working to modulate these risks through collaborative care and personalized interventions.
Declines in PSA testing varied by physician type, with primary care physicians showing a larger decrease than urologists. The study suggests that perceptions of PSA screening benefits and conflicting guidelines may contribute to the differences.
A new review suggests that targeted antibiotic therapy before prostate biopsy may lower sepsis rates. The study found 27 men need to receive antibiotics to prevent one infection, paving the way for safer procedures.
A new class of drug, YELIVA™ (ABC294640), has shown promise in slowing the growth of castration-resistant prostate cancer cells by inhibiting the sphingolipid pathway. The study found that treatment with YELIVA™ increased dihydroceramide levels and reduced expression of key oncogenes.
Researchers discovered a new biomarker, pro-NPY, which correlates with increased risk of prostate cancer death. The study suggests that high pro-NPY levels can predict prostate cancer-related death among diagnosed patients who haven't received surgical treatment.
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
A study found that 15.7% of individuals 65 or older received nonrecommended screenings for prostate and breast cancers due to limited life expectancy, costing the US healthcare system $1.2 billion annually. States with high rates of nonrecommended screening showed similar patterns in both prostate and breast cancer screenings.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
A recent study published in The Journal of Urology found that reduced prostate needle biopsies are associated with a higher risk of being diagnosed with high-risk disease. This could lead to delayed diagnosis and potentially avoidable cancer deaths. The study's findings highlight the need for balanced screening approaches and more effe...
A new study led by Sheffield Hallam University is exploring the potential of exercise as a treatment for prostate cancer. The PANTERA study involves 50 men with non-spreading cancer, who will either undergo supervised exercise sessions or receive information on exercise benefits but no sessions.*
A new study found that African American men with low-grade prostate cancer produce less PSA and have significantly lower PSA density than Caucasian men. This could lead to inaccurate surveillance criteria and affect treatment decisions for African American patients.
Researchers have found that screening male kidney transplant candidates for prostate cancer does not prolong their survival and may even delay receiving a transplant. Elevated PSA levels detected through screening were associated with a reduced likelihood of receiving a transplant regardless of the patient's age or PSA level.
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
Researchers discovered an unexpected link between two common prostate cancer treatments, radiation and androgen ablation. This connection allows doctors to better determine which treatment will benefit individual patients, potentially leading to improved prostate cancer treatments.
A meta-analysis of 19 studies involving over 118,000 patients found that surgery resulted in lower mortality rates compared to radiation treatment. Patients treated with surgery were twice as likely to survive prostate cancer than those treated with radiation.
Researchers at Houston Methodist Hospital developed a suicide gene therapy that combines radiation treatment with a genetically modified virus to target and destroy cancer cells. The treatment shows high five-year overall survival rates of 97% and 94%, improving upon historical studies by 5-20%.
A recent study found that PET/CT and whole-body MRI detect extraskeletal disease, changing cancer management. Combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed higher sensitivity and accuracy than alternative methods.
A new study from The Ottawa Hospital and the University of Ottawa found that repeating an abnormal PSA test reduces unnecessary biopsies by 55 percent. Men with conflicting test results who had a second normal test were diagnosed with cancer within a year, suggesting the importance of repeat testing.
A Stanford University study has found that men treated with androgen deprivation therapy for prostate cancer are nearly twice as likely to be diagnosed with Alzheimer's disease. The researchers analyzed electronic medical records of thousands of patients, revealing a significant increase in cognitive decline among those receiving ADT.
A new study published in Annals of Oncology shows that abiraterone acetate is effective in treating aggressive prostate cancers, even those with high Gleason scores. The treatment extended progression-free survival by up to 16.5 months in patients previously treated with docetaxel.
A UCLA study found that less than 5% of men with low-risk prostate cancer undergoing active surveillance receive regular monitoring, putting them at risk of cancer progression. The study suggests that patients and doctors should agree on a follow-up schedule to closely monitor the cancer.
A new drug combination is being tested for its effectiveness in treating metastatic prostate cancer. Researchers are optimistic about the results, citing improved quality of life and delayed disease progression in patients participating in a Phase 3 clinical trial.
PSA testing has declined dramatically in middle-aged men after a 2012 recommendation against routine screening, according to a new study. The biggest declines were seen in men ages 50-54 and 60-64 years old.
Researchers found that a secreted bone protein called Sclerostin inhibits prostate cancer metastasis to bone. The study also showed that lack of SOST in the bone microenvironment promotes expression of genes associated with cell migration and invasion.
Two studies found a decline in early-stage prostate cancer incidence and PSA-based screening rates among men 50 years and older following the 2012 USPSTF screening recommendations. The decline was most pronounced in younger men, with significant reductions in PSA screening rates observed between 2010 and 2013.
Men with prostate cancer who undergo radiation therapy can benefit from yoga, which stabilizes fatigue, sexual health, and urinary incontinence. Yoga also improves general quality of life by reducing cancer-related fatigue and strengthening pelvic floor muscles.
A new blood test for prostate cancer significantly improves detection of aggressive cancer, reducing false positives and unnecessary biopsies. The STHLM3 test analyzes protein markers, genetic data, and clinical information to detect cancers in men with low PSA values.
A new study by UCLA researchers reveals a wide range of costs for treating low-risk prostate cancer, with active surveillance being the most cost-effective option. The study used time-driven activity-based costing to analyze costs across an entire care process, finding significant variation in prices for different treatments.
A new clinical trial has shown that a gene-targeted drug, olaparib, can benefit up to 33% of patients with treatment-resistant advanced prostate cancer. The trial found that men whose tumours had defects in DNA repair machinery responded particularly well to the drug.
A new genetic discovery has identified a significant gene called miR137 that is switched off in prostate cancer cells, contributing to the disease's initiation and progression. The study also identified potential targets for next-generation drugs to treat prostate cancer.
Black men with localized prostate cancer had poorer quality care, higher costs, and worse postoperative outcomes compared to white men. However, the authors found no difference in cancer-specific or overall death between the two groups.
The RTOG 9601 study found that adding anti-androgen therapy to salvage radiotherapy improved overall survival and reduced prostate cancer death. The treatment also showed no significant increase in radiation toxicity.
Primary care providers should screen men aged 45 and older with a digital rectal exam (DRE) and prostate-specific antigen (PSA) test. If the patient is asymptomatic, a 5-year screening interval may be considered.
Researchers identified a key mechanism driving prostate cancer development, where normal cells undergo epigenetic reprogramming to form malignant growth. The study provides insights into the origins of prostate cancer and potential targets for prevention and treatment.
Researchers presented various applications of Bio-Rad's Droplet Digital PCR, including copy number determination, genome editing, and liquid biopsy. The technology demonstrated precision, reproducibility, and sensitivity in detecting complex genomic rearrangements and biomarker levels.
A new population-based study found no association between testosterone therapy and aggressive prostate cancer risk over a five-year period. The study analyzed data from Medicare linked records and included 52,579 men diagnosed with prostate cancer between 2001-2006.
The new guidelines promise to improve the detection of life-threatening tumors and reduce unnecessary biopsies, with the potential to save lives. The standards for acquiring and reporting MRI scans will be widely adopted, making it easier for doctors to identify significant cancers.
Researchers are investigating two new avenues for detection and treatment of advanced prostate cancer, focusing on biochemical reactions downstream of the androgen receptor. By targeting the metabolism of cancer cells, they aim to bypass ineffective drugs and develop new therapies.
New research analyzed data from the US Nationwide Inpatient Sample to identify prostate cancer risk factors. The study found that age, race, and family history are significant risk factors for prostate cancer, while obesity, alcohol abuse, and smoking show a protective effect.
A new trial has shown that giving patients fewer but higher doses of radiotherapy is as effective in treating prostate cancer as longer treatment periods. The study found that this approach resulted in fewer side effects and reduced the need for hospital visits, potentially saving over 150,000 trips per year.
A recent study found that reduced prostate specific antigen (PSA) screening led to a decline in intermediate and high-risk prostate cancer diagnoses by 28% over a year. However, this reduction also resulted in delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators.
A long-term follow-up study found that men with comorbidity and a prior heart attack who received androgen deprivation therapy had a higher risk of fatal heart attacks. The study suggests that treatment with radiation therapy alone may be a safer option for these patients.
A study suggests that radiation therapy alone is associated with decreased overall and cardiac mortality in men with unfavorable-risk prostate cancer and moderate or severe comorbidity. In contrast, the combination of radiation therapy and androgen deprivation therapy may not provide additional benefits for these patients.
A new imaging agent, Ga-68 PSMA, significantly improved detection of early recurrent prostate cancer in a study published in The Journal of Nuclear Medicine. The agent was found to detect sites of possible recurrence in 50% of patients with low PSA levels, compared to only 12.5% for another widely used agent.
Active surveillance can reduce overtreatment by almost 50 percent at 15 years, according to a new review article. The approach involves monitoring and testing patients with regular intervals, rather than immediate treatment. The authors found that this strategy can balance the risk of overdiagnosis and overtreatment in prostate cancer.
Researchers at Johns Hopkins Medicine analyzed survival statistics of 1,298 men with low-risk prostate tumors and found that only two died of prostate cancer after 15 years, while three developed metastatic disease. This suggests that carefully selected patients in active surveillance programs are unlikely to be harmed by their disease.
Researchers developed a molecular imaging biomarker that detects fast-growing primary prostate cancer and distinguishes it from benign prostate lesions. The new PSMA-based PET imaging technique was more specific than MR imaging for detecting clinically significant high-grade prostate cancer lesions.
Researchers have identified five distinct types of prostate cancer with unique genetic fingerprints, which could help doctors predict the aggressiveness of tumors and choose the best course of treatment. This breakthrough discovery has important implications for how prostate cancer is diagnosed and treated in the future.
Black men in England face a double lifetime risk of being diagnosed with and dying from prostate cancer compared to their white counterparts. The study reveals that Asian men have half the lifetime risk, highlighting the need for targeted awareness-raising and informed decision-making about PSA tests.
A new study using human embryonic stem cells suggests that early exposure to bisphenol A may lead to an increased risk of prostate cancer. The research found that BPA caused the development of prostate organoids to produce an overabundance of prostate stem cells, which could be a risk factor for cancer.